CUE vs SABS
CUE: Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate anti-tumor immunity in cancer. SABS: SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1 diabetes.
Side-by-side fundamentals
| Metric | CUE | SABS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.20 | $3.58 | |
| Market cap as of 2026-07-23 | $144M | $278M | |
| P/E as of 2026-07-23 | n/a | 20.97 | |
| Net margin as of 2026-07-23 | -59.6% | -1795.8% | CUE higher |
| Operating margin as of 2026-07-23 | -59.9% | -2388.9% | CUE higher |
| ROE as of 2026-07-23 | -98.3% | +15.2% | SABS higher |
| ROA as of 2026-07-23 | -53.7% | +12.5% | SABS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | CUE lower |
| Revenue growth (YoY) as of 2026-07-23 | +309.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +180.5% | n/a | |
| Beta as of 2026-07-23 | 2.49 | 0.56 | |
| 1-year return as of 2026-07-22 close | +26.3% | +34.8% | SABS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.